Next-generation sequencing (NGS) techniques enable sequencing ... we provide Perl scripts that can process data from all major platforms (Roche 454, Illumina Genome Analyzer and ABI SOLiD).

Additionally, catch up on recent company news and funding outcomes. This presentation provided an insight into Roche’s (Basel, Switzerland) novel next-generation sequencing technology, sequencing by ...

To overcome these challenges, researchers have integrated genomic sequencing into antimicrobial resistance surveillance. Through whole-genome sequencing, we can analyze all the DNA in a microbial ...

short sequencing time and reasonable amount of throughput, desktop sequencers such as Ion Torrent PGM, and its second-generation technology competitors, Illumina's MiSeq® and 454 GS Junior ...

with investors also concerned about Illumina’s product sales taking a hit due to U.S. research funding cuts and looming competition from Roche’s gene-sequencing device. Morningstar analyst Jul ...

Roche’s move into the digital pathology category has been boosted by FDA approval of a lab instrument and toolkit for use as an aid to clinical diagnosis. The clearance covers Roche’s Ventana ...

A linkurl:paper;http://www.pnas.org/cgi/doi/10.1073/pnas.0604351103 published this week in PNAS provides a possible glimpse at the near-term future of linkurl:next ...

Roche will present the new data at next week's ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma.

BRANFORD, Conn., March 26, 2025--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company ...

Under this co-promotional agreement, IDT will design, synthesize, and purify the fusion primers required for certain 454 Sequencing applications under this co-promotional agreement. GEI has awarded ...

Roche fails in bid to increase dose of MS drug ... said on Tuesday activist investor Keith Meister would join the gene-sequencing maker's board and former U.S. Food and Drug Administration ...